Sofinnova set to back dozens of biotechs with €1.2B across strategies

European firm Sofinnova expects to make up to 60 new investments from a €1.2 billion pool of capital raised in the past year, spanning four of its seven investment strategies across early- and late-stage life sciences companies.

Sofinnova Partners’ Antoine Papiernik told BioCentury that the firm expects to hold final closes in each strategy by year-end, with the final figure growing beyond €1.2 billion ($1.3 billion). Citing regulations, he declined to name which four strategies have raised new cash...